Treats hypertension. Sold as Bystolic. Every FDA application for this active ingredient: 1 branded and 19 generic.
As of Nov 15, 2026, FDA lists 20 applications for Nebivolol Hydrochloride (sold as Bystolic), first approved Dec 17, 2007, with 1 new use approved and 0 published complete response letters.
| Nebivolol HCl | Part D | $73.9M | -8% | 376,553 |
| Bystolic | Part D | $13.2M | -20% | 7,089 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes · Enhanced Emirates Limited | Not applicable | Enrolling by invitation | May 6, 2026 |
| The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.Heart Failure · Ziekenhuis Oost-Limburg | Phase 4 | Recruiting | Apr 7, 2026 |
| Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer PatientsHER2-positive Breast Cancer · Ain Shams University | Phase 2 | Recruiting | Nov 18, 2025 |
| Beta-blockers for Prevention of Supraventricular Arrhythmia Following PFO ClosureAtrial Fibrillation, Atrial Flutter · Yonsei University | Not applicable | Not yet recruiting | Aug 14, 2025 |
| Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT)Hypertension · A.Menarini Asia-Pacific Holdings Pte Ltd | — | Recruiting | Apr 22, 2025 |
| Nebivolol ANOCA Treatment Randomized TrialANOCA - Angina With Non-obstructive Coronary Arteries, Coronary Microvascular Dysfunction (CMD) · Spanish Society of Cardiology | Phase 3 | Not yet recruiting | Jan 1, 2025 |
| Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection FractionHeart Failure · Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | Jul 24, 2024 |
| Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary ArteriesAngina Pectoris, Microvascular Angina · Stanford University | Phase 2 / Phase 3 | Recruiting | May 22, 2024 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Allergan
Apotex